Virtual Library

Start Your Search

Pedram Razavi



Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-99 - Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China (ID 11285)

      16:45 - 18:00  |  Author(s): Pedram Razavi

      • Abstract
      • Slides

      Background

      Advances in NGS have led to an increase in identifying specific actionable gene alterations across tumor types. We collected data on HER2 gene alterations detected by NGS from patients with advanced NSCLC and analyzed clinical characteristics and HER2 targeted treatments.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Patients diagnosed with advanced NSCLC and underwent NGS testing from Jun 2014 to Dec 2017 at Memorial Sloan-Kettering Cancer Center (MSK) and Guangdong General Hospital (GGH) were included. NGS platforms were MSK-IMPACTTM in MSK and GeneSeek or BurnStone in GGH. Descriptive statistics are used in data analysis.

      4c3880bb027f159e801041b1021e88e8 Result

      2200 patients from MSK and 490 patients from GGH underwent NGS testing. HER2 mutation and/or amplification were detected in 91/2200(4.1%) patients and 28/490(5.7%) patients from MSK and GGH respectively. Clinical characteristics were listed in Table1. 37.4%(34/91) and 21.4%(6/28) patients from MSK and GGH received HER2 targeted therapies. More patients were enrolled to HER2 inhibitors clinical trials in MSK(24.2%) than GGH(7.1%). The characteristics of HER2 alterations are summarized in Table2.

      Table 1. Comparison of HER2 alterations in advanced NSCLC patients from U.S. and China

      MSK

      N (%)

      GGH

      N (%)

      Total Patients

      91

      28

      Age at Diagnosis (years)

      <=60

      34 (37.4%)

      13 (46.4%)

      >60

      57 (62.6%)

      15 (53.6%)

      Sex

      Male

      37 (40.7%)

      14 (50%)

      Female

      54 (59.3%)

      14 (50%)

      Smoking History

      Former/Current Smoker

      53 (58.2%)

      7 (25%)

      Non-Smoker

      38 (41.8%)

      21 (75%)

      Histology

      Adenocarcinoma

      84 (92.3%)

      25 (89.3%)

      Squamous Cell Carcinoma

      5 (5.5%)

      0

      Misc

      2 (2.2%)

      3 (10.7%)

      HER2 status

      Mutation

      48 (52.7%)

      16 (57.1%)

      Amplification

      32 (35.2%)

      11 (39.3%)

      Mutation + Amplification

      11 (12.1%)

      1 (3.6%)

      HER2 targeted treatment

      34 (37.4%)

      6 (21.4%)

      Enrolled to HER2 inhibitors clinical trials

      22 (24.2%)

      2 (7.1%)

      Table 2. HER2 alteration in advanced NSCLC patients from U.S. and China combined

      NGS Result

      Mutation Only

      N (%)

      Amplification Only

      N (%)

      Mutation + Amplification

      N (%)

      Total Patients 64 43 12

      Age at Diagnosis (years)

      <=60

      31 (48.4%)

      20 (46.5%)

      8 (66.7%)

      >60

      33 (51.6%)

      23 (35.9%)

      4 (33.3%)

      Sex

      Male

      39 (60.9%)

      19 (44.2%)

      7 (58.3%)

      Female

      25 (39.1%)

      24 (55.8%)

      5 (41.7%)

      Smoking History

      Former/Current Smoker

      31 (48.4%)

      24 (55.8%)

      5 (41.7%)

      Non-Smoker

      33 (51.6%)

      19 (44.2%)

      7 (58.3%)

      Histology

      Adenocarcinoma

      58 (90.6%)

      39 (90.7%)

      12 (100%)

      Squamous Cell Carcinoma

      1 (1.6%)

      4 (9.3%)

      0

      Misc

      5 (7.5%)

      0

      0

      HER2 targeted treatment

      Yes

      19 (29.7%)

      14 (32.6%)

      7 (58.3%)

      No

      45 (70.3%)

      29 (67.4%)

      5 (41.7%)

      8eea62084ca7e541d918e823422bd82e Conclusion

      The incidence and clinical characteristics of HER2 alterations in advanced NSCLC were similar between two large cancer centers in the U.S. and China. These data support U.S.-China collaboration in clinical trials for patients with rare molecular subsets of NSCLC to accelerate new cancer drug development.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.